Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?

Expert Review of Hematology

Volumn 6, Issue 5, 2013, Pages 539-542

  Zeidan, Amer M ^a   Gore, Steven D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

allogeneic stem cell transplantation; decision analysis; myelodysplastic syndromes; reduced intensity conditioning

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; COMPARATIVE STUDY; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MYELODYSPLASTIC SYNDROME; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SENESCENCE; TREATMENT OUTCOME;

FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; TRANSPLANTATION CONDITIONING;

EID: 84885907960     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2013.827097     Document Type: Note

References (22)

1. Zeidan AM. Linhares Y, Gore S. Current therapy of myelodysplastic syndromes. Blood Rev. (2013) (In Press).
2. Raza A, Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat. Rev. Cancer 12(12), 849-859 (2012).
3. Ma X. Epidemiology of myelodysplastic syndromes. Am. J. Med. 125(Suppl. 7), S2-S5 (2012).
4. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6), 2079-2088 (1997).
5. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 10(3), 223-232 (2009).
6. Deeg HJ, Bartenstein M. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status. Arch. Immunol. Ther. Exp. (Warsz) 60(1), 31-41 (2012).
7. Giralt SA, Horowitz M, Weisdorf D, Cutler C. Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the decision memo for allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome emanating from the centers for medicare and medicaid services. J. Clin. Oncol. 29(5), 566-572 (2011).
8. Sekeres MA, Schoonen WM, Kantarjian H et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J. Natl Cancer Inst. 100(21), 1542-1551 (2008).
9. Platzbecker U, Schetelig J, Finke J et al. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol. Blood Marrow Transplant. 18(9), 1415-1421 (2012).
10. Koreth J, Pidala J, Perez WS et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J. Clin. Oncol. (2013) (Epub ahead of print).
11. Zeidan AM, Komrokji RS. There's risk, and then there's RISK: The latest clinical prognostic risk stratification models in myelodysplastic syndromes. Curr. Hematol. Malig. Rep. (2013) (In Press).
12. Sekeres MA. Bone marrow transplantation (BMT) in myelodysplastic syndromes: to BMT or not to BMT-that is the question. J. Clin. Oncol. 31(21), 2643-2644 (2013).
13. Cutler CS, Lee SJ, Greenberg P et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104(2), 579-585 (2004).
14. McClune BL, Weisdorf DJ, Pedersen TL et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J. Clin. Oncol. 28(11), 1878-1887 (2010).
15. Koreth J, Aldridge J, Kim HT et al. Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol. Blood Marrow Transplant. 16(6), 792-800 (2010).
16. Alyea EP, Kim HT, Ho V et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol. Blood Marrow Transplant. 12(10), 1047-1055 (2006).
17. Scott BL, Sandmaier BM, Storer B et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20(1), 128-135 (2006).
18. Prebet T, Gore SD, Esterni B et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J. Clin. Oncol. 29(24), 3322-3327 (2011).
19. Garcia-Manero G, Shan J, Faderl S et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22(3), 538-543 (2008).
20. Zeidan AM, Smith BD, Komrokji RS, Gore SD. Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS). Am. J. Med. 126(4), e25 (2013).
21. Greenberg PL, Tuechler H, Schanz J et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12), 2454-2465 (2012).
22. Faltas B, Zeidan A, Gergis U. Myelodysplastic syndromes: towards a risk-adaptive treatment approach. Expert. Rev Hematol. (2013) (In Press).